Innovent Biologics initiates Phase IV trial of Teprotumumab for Thyroid Eye Disease
Innovent Biologics is conducting Phase IV trial of teprotumumab N01 in 92 participants with active thyroid eye disease, comparing it to intravenous glucocorticoids.
Asset / Drug
Drug and asset intelligence for Teprotumumab with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.